Eversept Partners LP grew its stake in Pfenex Inc (NYSEAMERICAN:PFNX) by 7.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,968 shares of the biotechnology company’s stock after purchasing an additional 5,268 shares during the quarter. Eversept Partners LP’s holdings in Pfenex were worth $546,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of PFNX. BNP Paribas Arbitrage SA lifted its holdings in shares of Pfenex by 2,127.7% in the first quarter. BNP Paribas Arbitrage SA now owns 6,037 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 5,766 shares in the last quarter. Falcon Point Capital LLC lifted its holdings in Pfenex by 3.5% during the first quarter. Falcon Point Capital LLC now owns 83,005 shares of the biotechnology company’s stock worth $513,000 after acquiring an additional 2,800 shares during the period. RK Capital Management LLC bought a new stake in Pfenex during the first quarter worth $1,864,000. Weiss Asset Management LP bought a new stake in Pfenex during the first quarter worth $81,000. Finally, Janus Henderson Group PLC bought a new stake in Pfenex during the second quarter worth $91,000.

Pfenex stock traded up $0.11 during mid-day trading on Friday, reaching $9.80. 47,379 shares of the company’s stock were exchanged, compared to its average volume of 155,386. Pfenex Inc has a one year low of $3.13 and a one year high of $9.70.

Pfenex (NYSEAMERICAN:PFNX) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.07. The business had revenue of $2.81 million for the quarter, compared to the consensus estimate of $5.65 million.

In related news, insider Patrick K. Lucy sold 6,000 shares of Pfenex stock in a transaction on Friday, September 6th. The stock was sold at an average price of $8.00, for a total transaction of $48,000.00.

A number of analysts recently commented on the company. JMP Securities lifted their price target on Pfenex from $13.00 to $17.00 and gave the stock an “outperform” rating in a report on Wednesday. Zacks Investment Research upgraded Pfenex from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Thursday, August 15th.

Pfenex Company Profile

Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.

Read More: Resistance Level

Want to see what other hedge funds are holding PFNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfenex Inc (NYSEAMERICAN:PFNX).

Institutional Ownership by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.